What are the main functions of Pirfenidone/Axri? What lung diseases is it suitable for?

Pirfenidone is an oral anti-fibrotic drug mainly used to treat idiopathic pulmonary fibrosis (IPF). Idiopathic pulmonary fibrosis is a progressive lung disease characterized by fibrosis of lung tissue, which gradually leads to loss of lung function and may eventually lead to death. The main effect of pirfenidone is to inhibit the fibrosis process of the lungs, slow down the progression of the disease, and help improve the patient's quality of life.

The mechanism of action of pirfenidone is not fully understood, but research shows that it exerts its anti-fibrotic effects through multiple pathways. First, pirfenidone can inhibit the TGF-β (transforming growth factor-β) signaling pathway. TGF-β plays a central role in the occurrence and progression of fibrosis. It can promote the proliferation of fibroblasts and collagen synthesis, leading to the formation of fibrosis. By inhibiting this pathway, pirfenidone effectively slows the process of fibrosis. Secondly, pirfenidone also has antioxidant and anti-inflammatory effects, which further enhance its inhibitory effect on fibrosis. Studies have shown that pirfenidone can reduce the inflammatory response in the lungs and reduce cell damage caused by inflammation, thereby inhibiting the occurrence of fibrosis.

Pirfenidone is mainly used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic and rapidly progressive lung disease. The main characteristics of IPF are abnormal proliferation and fibrosis of the alveolar interstitium, and the main symptoms are usually shortness of breath, persistent dry cough and fatigue. As the disease progresses, patients will develop significant pulmonary dysfunction, affecting their quality of daily life and significantly shortening their survival. Since the cause of IPF is not fully understood and treatments are limited, the emergence of pirfenidone provides patients with an effective treatment option. It improves patients' survival and quality of life by slowing down the decline of lung function, especially when treated early.

Reference materials:https://www.esbriet.com/